Risk factor
Limited trading liquidity
Profitability factor
Undervalued vs peers
About
Chong Kun Dang Pharmaceutical Corp. develops, promotes, and distributes a comprehensive array of medical and health-related goods. The company operates extensively, catering to the South Korean domestic market and extending its reach internationally through exports. Its offerings encompass critical prescription drugs, such as treatments for high blood pressure, high cholesterol, and diabetes. Additionally, it provides popular over-the-counter remedies like Penzal, Prefemine, and Modcol, alongside various consumer health commodities including insecticides and hair dyes. A significant part of its portfolio also includes health supplements aimed at disease prevention. Established in 1941, Chong Kun Dang Pharmaceutical Corp. maintains its principal office in Seoul, South Korea.
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is fairly valued on P/E, undervalued on EV/EBITD.
Target Price
The average target price of 185750.KS is 121134 and suggests 77.6% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation